This review discusses the evidence in support of the use of Apremilast, its pharmacological properties, dosage and administration, and efficacy and tolerability as demonstrated in pivotal clinical trials. It also provides commentary and recommendations from Clinical Associate Professor Kurt Gebauer, a Dermatologist working in private practice in Fremantle.
Please login below to download this issue (PDF)